Basilea Pharmaceutica (SWX:BSLN) is back in focus after reporting half year 2026 results on 18 August, with higher revenue and net income, and issuing upgraded full year revenue and operating profit guidance. See our latest analysis for Basilea Pharmaceutica. The earnings beat and raised guidance have coincided with a sharp pickup in momentum for Basilea Pharmaceutica, with a 30 day share price return of 25.19% and a 1 year total shareholder return of 38.11%. If this kind of move has your...

Strong first-half performance driven by Cresemba royalties and non-dilutive funding, with pipeline progress on track.